FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204253027> ?p ?o ?g. }

• W3204253027 abstract "Background Myelin oligodendrocyte glycoprotein-antibody (MOG-ab)-associated disease (MOGAD) has highly heterogenous clinical and imaging presentations, in which encephalitis is an important phenotype. In recent years, some atypical presentations in MOG-ab-associated encephalitis (MOG-E) have been increasingly reported but have not yet been described well. The aim of the study was to describe the clinical and imaging features of patients with MOG-E in our center. Atypical phenotypes would be reported, which is expected to expand the spectrum of MOGAD. Methods We reviewed medical records of 59 patients with MOGAD diagnosed in our center and identified cases who had ever experienced encephalitic symptoms. Three hundred ten patients with autoimmune encephalitis (AE) were also reviewed, and cases with positive MOG-ab were identified. Besides, patients with chronically progressive encephalitis were identified from 13 MOG-E and 310 AE patients. We collected demographic, clinical, laboratory, radiological, and outcome data to explore clinical and imaging characteristics in MOG-E, especially in the atypical phenotype of chronically progressive encephalitis. Results We identified 13 patients (7 males, 6 females) with MOG-E. The median age at onset was 33 years (range 13~62 years). Most (9/13, 69.2%) of patients showed acute or subacute onset of encephalitic symptoms. Brain MRI abnormalities were observed in all patients. The most common lesion locations on MRI were cortical/subcortical (11/13, 84.6%), deep/periventricular white matter (10/13, 76.9%) and corpus callosum (4/13, 30.8%). Brain MRI patterns were categorized into four phenotypes. The most common pattern was cortical encephalitis with leptomeningeal enhancement/brain atrophy (10/13, 76.9%). Eight (8/13, 61.5%) patients had a good response to immunotherapy. Four (4/13, 30.8%) patients with chronically progressive course were identified from MOG-E cohort. They showed leukodystrophy-like pattern, multifocal hazy lesions, or cortical encephalitis on MRI. With immunotherapy, they only showed mild or no improvement. We also identified four (4/310, 1.3%) patients with chronically progressive course from AE cohort. They had better outcomes than counterparts in MOG-E. Conclusions This study demonstrates that encephalitic presentations in MOGAD had complex clinical patterns. Chronically progressive encephalitis may be a new phenotype of MOGAD. We recommend to test MOG-ab in subacute and chronic progressive dementia with leukodystrophy-like MRI lesions." @default.
• W3204253027 created "2021-10-11" @default.
• W3204253027 creator A5002413621 @default.
• W3204253027 creator A5004512291 @default.
• W3204253027 creator A5004686020 @default.
• W3204253027 creator A5007612266 @default.
• W3204253027 creator A5013962180 @default.
• W3204253027 creator A5017858894 @default.
• W3204253027 creator A5019609564 @default.
• W3204253027 creator A5021549046 @default.
• W3204253027 creator A5027024342 @default.
• W3204253027 creator A5034960788 @default.
• W3204253027 creator A5036367482 @default.
• W3204253027 creator A5039548850 @default.
• W3204253027 creator A5040253417 @default.
• W3204253027 creator A5045117407 @default.
• W3204253027 creator A5060313829 @default.
• W3204253027 creator A5063213559 @default.
• W3204253027 creator A5065771969 @default.
• W3204253027 creator A5066976368 @default.
• W3204253027 creator A5080397227 @default.
• W3204253027 creator A5088910755 @default.
• W3204253027 creator A5091103390 @default.
• W3204253027 creator A5091248983 @default.
• W3204253027 date "2021-10-07" @default.
• W3204253027 modified "2023-10-10" @default.
• W3204253027 title "Clinical and Imaging Features of Patients With Encephalitic Symptoms and Myelin Oligodendrocyte Glycoprotein Antibodies" @default.
• W3204253027 cites W1482033427 @default.
• W3204253027 cites W2013234597 @default.
• W3204253027 cites W2158227195 @default.
• W3204253027 cites W2162978315 @default.
• W3204253027 cites W2280783985 @default.
• W3204253027 cites W2524845362 @default.
• W3204253027 cites W2544079919 @default.
• W3204253027 cites W2578761578 @default.
• W3204253027 cites W2767386734 @default.
• W3204253027 cites W2768094726 @default.
• W3204253027 cites W2779296356 @default.
• W3204253027 cites W2783429334 @default.
• W3204253027 cites W2795316771 @default.
• W3204253027 cites W2801748653 @default.
• W3204253027 cites W2806973999 @default.
• W3204253027 cites W2884626427 @default.
• W3204253027 cites W2888355099 @default.
• W3204253027 cites W2890180037 @default.
• W3204253027 cites W2899992638 @default.
• W3204253027 cites W2905137679 @default.
• W3204253027 cites W2912090683 @default.
• W3204253027 cites W2922619806 @default.
• W3204253027 cites W2923277628 @default.
• W3204253027 cites W2941915623 @default.
• W3204253027 cites W2945083001 @default.
• W3204253027 cites W2972680623 @default.
• W3204253027 cites W2990963627 @default.
• W3204253027 cites W2991738025 @default.
• W3204253027 cites W2995476039 @default.
• W3204253027 cites W3004592781 @default.
• W3204253027 cites W3006216901 @default.
• W3204253027 cites W3007426859 @default.
• W3204253027 cites W3012069134 @default.
• W3204253027 cites W3021236134 @default.
• W3204253027 cites W3021817318 @default.
• W3204253027 cites W3027961449 @default.
• W3204253027 cites W3035567896 @default.
• W3204253027 cites W3045354779 @default.
• W3204253027 cites W3046494467 @default.
• W3204253027 cites W3048776195 @default.
• W3204253027 cites W3150682065 @default.
• W3204253027 cites W3160102114 @default.
• W3204253027 doi "https://doi.org/10.3389/fimmu.2021.722404" @default.
• W3204253027 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8529193" @default.
• W3204253027 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34691028" @default.
• W3204253027 hasPublicationYear "2021" @default.
• W3204253027 type Work @default.
• W3204253027 sameAs 3204253027 @default.
• W3204253027 citedByCount "10" @default.
• W3204253027 countsByYear W32042530272022 @default.
• W3204253027 countsByYear W32042530272023 @default.
• W3204253027 crossrefType "journal-article" @default.
• W3204253027 hasAuthorship W3204253027A5002413621 @default.
• W3204253027 hasAuthorship W3204253027A5004512291 @default.
• W3204253027 hasAuthorship W3204253027A5004686020 @default.
• W3204253027 hasAuthorship W3204253027A5007612266 @default.
• W3204253027 hasAuthorship W3204253027A5013962180 @default.
• W3204253027 hasAuthorship W3204253027A5017858894 @default.
• W3204253027 hasAuthorship W3204253027A5019609564 @default.
• W3204253027 hasAuthorship W3204253027A5021549046 @default.
• W3204253027 hasAuthorship W3204253027A5027024342 @default.
• W3204253027 hasAuthorship W3204253027A5034960788 @default.
• W3204253027 hasAuthorship W3204253027A5036367482 @default.
• W3204253027 hasAuthorship W3204253027A5039548850 @default.
• W3204253027 hasAuthorship W3204253027A5040253417 @default.
• W3204253027 hasAuthorship W3204253027A5045117407 @default.
• W3204253027 hasAuthorship W3204253027A5060313829 @default.
• W3204253027 hasAuthorship W3204253027A5063213559 @default.
• W3204253027 hasAuthorship W3204253027A5065771969 @default.
• W3204253027 hasAuthorship W3204253027A5066976368 @default.
• W3204253027 hasAuthorship W3204253027A5080397227 @default.
• W3204253027 hasAuthorship W3204253027A5088910755 @default.
• W3204253027 hasAuthorship W3204253027A5091103390 @default.

• next